Home » Stocks » ADAP

Adaptimmune Therapeutics PLC (ADAP)

Stock Price: $3.65 USD -0.01 (-0.14%)
Updated Jul 29, 2021 12:11 PM EDT - Market open
Market Cap 574.30M
Revenue (ttm) 3.63M
Net Income (ttm) -139.69M
Shares Out 155.50M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $3.65
Previous Close $3.65
Change ($) -0.01
Change (%) -0.14%
Day's Open 3.69
Day's Range 3.63 - 3.75
Day's Volume 134,452
52-Week Range 3.37 - 10.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and pr...

1 day ago - GlobeNewsWire

The biotech's shares have definitely lost their shine in 2021.

1 week ago - The Motley Fool

These unloved cancer stocks should dramatically outperform Dogecoin over the long haul.

Other stocks mentioned: VSTM
1 month ago - The Motley Fool

With the trading day more than halfway over, the markets were moving higher going into the weekend.

Other stocks mentioned: DG, JNJ, HPQ, GES, TDOC
2 months ago - 24/7 Wall Street

A key pipeline drug performs well in a mid-stage clinical trial.

2 months ago - The Motley Fool

Adaptimmune Therapeutics plc (NASDAQ: ADAP) revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4). Data will be presented at the Ame...

2 months ago - Benzinga

- Data will support BLA filing for afamitresgene autoleucel next year -

2 months ago - GlobeNewsWire

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS: ALPMF) T...

2 months ago - Benzinga

- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells -

2 months ago - GlobeNewsWire

- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO -

2 months ago - GlobeNewsWire

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical dat...

3 months ago - GlobeNewsWire

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 22, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and p...

3 months ago - GlobeNewsWire

- Outlined strategy to build integrated cell therapy company and the Company's “2-2-5-2” five-year core value drivers -

5 months ago - GlobeNewsWire

Immense potential, TCR therapy leader, but early stage. Science looks excellent with some proof of concept but risks, especially toxicity risks, abound.

7 months ago - Seeking Alpha

- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

8 months ago - GlobeNewsWire

- Data support confidence in SPEARHEAD-1 as a registrational trial -

8 months ago - GlobeNewsWire

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on ...

8 months ago - GlobeNewsWire

- Data support continued development of ADP-A2M4CD8 -

8 months ago - GlobeNewsWire

Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.

Other stocks mentioned: TRIL
8 months ago - The Motley Fool

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients -

8 months ago - GlobeNewsWire

PHILADELPHIA and OXFORDSHIRE, U.K., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a bu...

9 months ago - GlobeNewsWire

An early abstract release has shareholders in panic mode today.

9 months ago - The Motley Fool

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the earl...

9 months ago - GlobeNewsWire

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: CCXI, KOD, MCRB, MYOV, NVAX, SRNE
10 months ago - InvestorPlace

Following the resurgence from the coronavirus bear market of 2020, Adaptimmune yielded multiple fold gains from its lows earlier in the year.

10 months ago - Seeking Alpha

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data fro...

11 months ago - GlobeNewsWire

Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11 months ago - Zacks Investment Research

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -

11 months ago - GlobeNewsWire

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medici...

1 year ago - GlobeNewsWire

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and ...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc (ADAP).

1 year ago - Zacks Investment Research

Adaptimmune Therapeutics (ADAP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Can an early-stage cancer immunotherapy company deliver riches to shareholders?

1 year ago - The Motley Fool

The biotech continued its winning ways.

1 year ago - The Motley Fool

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced th...

1 year ago - GlobeNewsWire

Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced th...

1 year ago - GlobeNewsWire

Adaptimmune prudently decided to take advantage of its soaring share price to raise capital.

1 year ago - The Motley Fool

Shares of Adaptimmune Therapeutics PLC ADAP, +127.77% tumbled 11% in premarket trading Monday, after the biopharmaceutical company focused on cancer treatments said it planned a public offering of 12.5 ...

1 year ago - Market Watch

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced th...

1 year ago - GlobeNewsWire

Positive results from a handful of patients treated have bolstered confidence in the company's cell-based approach to cancer treatment.

1 year ago - The Motley Fool

Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) shares were advancing strongly Friday following an updated clinical readout from the company.

1 year ago - Benzinga

Adaptimmune Therapeutics PLC (NASDAQ: ADAP) shares jumped on Friday after the company announced updated data from its early-stage clinical trial in patients with lung, head and neck cancers.

1 year ago - 24/7 Wall Street

- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy -

1 year ago - GlobeNewsWire

Big pharma partners could help this cutting-edge cell-therapy company be successful in the future.

1 year ago - The Motley Fool

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.

1 year ago - Benzinga

- Upfront payment of $50m received from Astellas and approximately $90m offering completed -

1 year ago - GlobeNewsWire

About ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and n... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2015
Stock Exchange
NASDAQ
Ticker Symbol
ADAP
Full Company Profile

Financial Performance

In 2020, ADAP's revenue was $3.96 million, an increase of 252.76% compared to the previous year's $1.12 million. Losses were -$130.09 million, -5.16% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is 10.29, which is an increase of 182.30% from the latest price.

Price Target
$10.29
(182.30% upside)
Analyst Consensus: Buy